Chimpanzee adenovirus– and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.

Authors :: Green, Christopher A.
Scarselli, Elisa
Sande, Charles J.
Thompson, Amber J.
de Lara, Catherine M.
Taylor, Kathryn S.
Haworth, Kathryn
Sorbo, Mariarosaria Del
Angus, Brian
Siani, Loredana
Di Marco, Stefania
Traboni, Cinzia
Folgori, Antonella
Colloca, Stefano
Capone, Stefania
Vitelli, Alessandra
Cortese, Riccardo
Klenerman, Paul
Nicosia, Alfredo
Pollard, Andrew J.
Source :: Science Translational Medicine; 8/12/2015, Vol. 7 Issue 300, p1-16, 16p, 1 Diagram, 1 Chart, 5 Graphs
Publication Year :: 2015
Abstract: The article offers information on the efficacy of chimpanzee adenovirus, PanAd3-RSV, and modified vaccinia virus Ankara, MVA-RSV in the vaccination of respiratory syncytial virus (RSV) infection. It mentions the limitation of palivizumab monoclonal antibody prophylaxis; talks about the absence of immunopathology associated with enhanced respiratory disease (ERD) after vaccination; and investigated the cellular immunogenicity of the vaccines.

Subjects :: RESPIRATORY syncytial virus infection vaccines
PALIVIZUMAB
MONOCLONAL antibodies
PREVENTIVE medicine
IMMUNOPATHOLOGY
RESPIRATORY diseases
THERAPEUTICS

Full Text Access

Tools